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  Xenotransplantation is a new technology that may help to overcome the shortage of human tissues and or-
gans available for the treatment of tissue and organ failure. Remarkable progress has recently been made in 
this field. First, understanding of the mechanisms of immunological rejection, mainly of the hyperacute rejec-
tion, allowed generating numerous genetically modified pigs to overcome rejection. Second, based on these 
genetically modified animals and new immunosuppression regimens, long-term survival of non-human pri-
mate recipients of heart, kidney, and islet cell cells has been reported. And third, potential zoonotic microor-
ganisms have been identified in pigs and sensitive methods to detect them have been generated. In 2 clinical 
trials treating diabetic patients with porcine islet cells, no porcine microorganisms were transmitted to human 
recipients. Furthermore, strategies to eliminate potentially zoonotic microorganisms from donor pigs in order to 
prevent transmission to the recipients have been developed, including designated pathogen-free (DPF) breed-
ing. In addition, strategies to prevent transmission of porcine endogenous retroviruses (PERVs) have been de-
veloped, including a knockout of all proviruses in the pig genome by gene editing. PERVs are integrated in the 
genome of all pigs and therefore they cannot be eliminated by DPF breeding. Since they are able to infect hu-
man cells, they represent a special risk in xenotransplantation. Despite the achievements, some problems re-
main: numerous genetically multi-modified pigs have been generated without fully evaluating their advantage, 
and microbiological screening of pigs to be used for transplantations and elimination of pathogenic microor-
ganisms from the donor pigs are still not satisfactory.
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Background
The shortage of human organs for the treatment of tissue and 
organ failure is well known. There are several ways to cope with 
this: prevention of diseases leading to organ failure, increase 
of the number of human donors, and implantable electrome-
chanical devices, which have been explored in the field of car-
diac transplantation. However, these strategies will not be a 
solution for most of the patients on the waiting list. An alter-
native would be to create vascularized organs from stem cells, 
which is currently far from reality. Another solution could be 
xenotransplantation, which is transplantation of cells, tissues, 
or organs from another species. Pigs are for many reasons (e.g., 
size, physiology, large number of progeny, and genetic modifi-
cation) the favored donor species. Xenotransplantation using 
pig cells, tissues and organs has to overcome 3 hurdles before 
being applied in the clinic (Figure 1): immunological rejection, 
physiological incompatibility, and risk of transmission of po-
tentially pathogenic microorganisms, which may induce a zoo-
nosis. Microbiological safety is very important and porcine en-
dogenous retroviruses (PERVs) are of special interest because 
they are integrated in the genome of all pigs and cannot be 
eliminated (like many other potentially zoonotic pig microor-
ganisms) by specified or designated pathogen-free (SPF or DPF) 
breeding. Here we summarize the recent successes in the field.
Immunological Rejection
In comparison to allotransplantation, the immunological rejec-
tion of pig tissues and organs is much more complex. The first 
step of immunological rejection in xenotransplantation is hy-
peracute rejection (HAR), which is well studied. HAR is based 
on pre-existing antibodies directed mainly against galactose-
a 1,3-galactose [Gala13Galb1- [3]4GlcNAc-R, a-gal] epitopes. 
The a-gal epitope is abundantly synthesized on glycolipids and 
glycoproteins of non-primates and New World monkeys by the 
glycosylation enzyme a1,3galactosyltransferase (a1,3GT) [1]. 
In humans, apes, and Old World monkeys, this epitope is ab-
sent because the a1,3GT gene was inactivated in ancestral Old 
World primates. Instead, humans, apes, and Old World mon-
keys produce anti-Gal antibodies, which specifically interact 
with a-gal epitopes and which constitute ~1% of circulating 
immunoglobulins [1]. Since a-gal epitopes are present on the 
surface of bacterial cells and cells from other animals, the an-
tibodies directed against the a-gal epitope represent a power-
ful tool to protect against bacterial infection, as well as from 
the transmission of foreign cells. When anti-Gal antibodies in-
teract with pig cells, they activate complement and induce the 
rejection of the pig transplant [2]. Based on this knowledge, 
transgenic animals were created, overcoming the rejection pro-
cess. There are 2 ways to prevent rejection: by a knockout of 
the cellular enzyme a1,3GT (GTKO pigs), which is adding a-gal 
epitopes to pig cell surface molecules [3], and by expression 
of human complement-regulatory proteins such as hCD46, 
hCD55, and hCD59 on pig cells (for review, see [4]). Animals 
expressing different combinations of the complement-regu-
latory proteins have been created (for overview, see Table 2 
in [5]). In addition, immune T cell responses were reduced by 
simultaneous expression of CTLA4-IgG and mutant MHC class 
II transactivator [6–9].
a-gal epitopes and 2 N-glycoylneuraminic acid-terminated 
(Neu5Gc) gangliosides are targets for pre-existing antibodies 
in human sera [10]. The expression of Neu5Gc is also specific 
for pigs and some other animals, but not for humans, because 
the corresponding enzyme, cytidine monophosphate-N-acetyl-
neuramic acid hydrolase (CMAH), was inactivated during pri-
mate evolution [11]. Double-knockout pigs deficient in a-gal 
and Neu5Gc significantly reduce the humoral barrier to xeno-
transplantation [11]. Using zinc finger nuclease (ZFN) technol-
ogy, GGTA1/CMAH knockout pigs were produced [11], which 
were characterized by a reduced binding of human antibod-
ies to transgenic peripheral blood mononuclear cells (PBMCs) 
in vitro [12]. In lung perfusion experiments, hCD46 expression 
in GTKO pigs down-regulated complement activation, dimin-
ished platelet and coagulation cascade activation, neutrophil 
sequestration, and histamine release [13]. Altogether, trans-
plants from these genetically modified pigs are characterized 
by significantly reduced rejection.
When HAR is averted, xenotransplants become subject to acute 
vascular rejection (named because of its similarity to acute vas-
cular rejection in allotransplantation), also called acute humor-
al xenotransplant rejection (AHXR) or delayed xenotransplant 
rejection. Expression of human proteins involved in endotheli-
al activation, such as heme oxygenase 1 (HO-1) [14] or tumor 
necrosis factor-induced human protein A20 [15], as well as of 
human antithrombotic or anticoagulant genes such as tissue 
factor pathway inhibitor (TFPI), endothelial protein C receptor 
(EPCR), or thrombomodulin (TM), may also enhance xenotrans-
plant survival [16]. In the case of islet preparations, cellular re-
actions usually play the dominant role in islet xenotransplant 
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rejection. Blocking T cell activation by antigen-presenting cells 
(APC) via interfering with the co-stimulatory systems CD40-
CD40L and/or CD80/86-CD28 could be utilized to reduce this 
reaction [17–21]. In a pig-to-humanized mouse transplanta-
tion, transgenic porcine islet cell clusters expressing the T cell 
costimulation blocking molecule LEA29Y normalized blood 
glucose levels of diabetic mice and were, in contrast to wild-
type porcine islets, protected against rejection by human im-
mune cells [22]. T cell activation is regulated by co-stimula-
tory as well as by co-inhibitory receptor-ligand interactions. 
Enhancing inhibitory signals by transgenic expression of re-
spective ligands on porcine cells is an attractive new concept 
to diminish human anti-pig cellular immune responses [23]. 
The observation that immune responses to pig cells overex-
pressing the human inhibitory ligand PD-L1 (CD274) are par-
ticularly weak in vitro and in vivo supports the relevance of this 
approach [24,25]. It was proposed that combining blockade of 
co-stimulatory signalling pathways (e.g., by CTLA-4.Ig/LEA29Y) 
with an enhancement of inhibitory signals by targeting the 
PD-1/PD-L1 pathway should be highly effective in controlling 
cell-mediated rejection of xenotransplants [26]. Regulatory T 
cells (Tregs) represent another approach to inhibit T cell-me-
diated rejection [27,28]. In addition, natural killer (NK) cells, 
macrophages, and neutrophils are critical components of the 
cellular response in xenotransplant rejection [29–31]. For ex-
ample, expression of HLA-E, an inhibitor of NK cell activation, 
has been found to protect porcine cells from destruction by 
primate NK cells [32]. T cell responses against the xenotrans-
plant are closely associated with immediate blood-mediated 
inflammatory reaction (IBMIR) [33, 34] and the resulting acti-
vation of complement factors and coagulation [34].
Numerous genetically-altered pigs have been generated, but 
their real advantage for the survival of pig cells, tissues, and 
organs has not been evaluated.
Increased Survival Times
Due to the newly generated genetically modified pigs and new 
and effective immunosuppressive treatments preventing anti-
body and immune T cell responses, a prolonged survival of the 
transplants was observed. A comprehensive overview of the 
experimental transplantations in the years until 2013 is giv-
en by Cooper et al. [35]. To demonstrate the development in 
the field, the longest survival times listed by Cooper et al. [35] 
and survival times published later [6,36–43] are summarized 
in Tables 1 and 2. The ability to modify pigs genetically to pro-
tect the donor organs from the primate’s immune response 
has resulted in survival of heterotopic pig hearts in baboons 
for longer than 2.5 years [39–41,44,45] (Table 1). Increase in 
immunosuppression, but not in anticoagulation, improved het-
erotopic GTKO pig heart survival in baboons [46].
In contrast to the heterotopic heart xenotransplantations, 
the survival time of orthotopic xenotransplantations is much 
shorter (at present, up to 57 days; Table 1). In this context it 
seems useful to remember the initial survival times in the first 
clinical heart allotransplantations; the first recipient lived for 
18 days and the second for 19 months (for a historical over-
view, see [47]).
Life-supporting pig kidneys survived for almost 3 months in 
NHP [48, 49] (Table 1). Expression of human complement path-
way-regulatory proteins, hCD46 or hCD55, in combination with 
GTKO reduced the incidence of early transplant failure (loss 
of function within 3 days of transplantation) to 7%, but did 
not prevent systemic coagulation activation [50]. Encouraging 
results were obtained when a GTKO pig transgenic for CD46, 
CD55, thrombomodulin (TBM), endothelial proteins C recep-
tor (CD39), and blood type 0 donor was used. Although the 
expression of CD39 and TBM was low, a kidney from this ani-
mal transplanted under an effective immunosuppressive thera-
py and using anti-inflammatory agents was functional for 136 
days [8, 42] (Table 1). A survival time of over 125 days was ob-
served when kidneys from CTKO/CD55 pigs were transplanted 
and the recipients were treated with anti-CD154 monoclonal 
antibodies [41]. Experience with pig liver xenotransplantation, 
however is sparse, with maximum graft survival in the NHP of 
only 9 days [51–53].
Physiological Compatibility
At present, the physiological compatibility is difficult to evalu-
ate since the survival time of the transplanted organs is usual-
ly too short to analyze the long-term functionality of the trans-
plant and its interaction with the transplant recipient in detail. 
When the physiological aspects of pig to non-human primate 
renal xenotransplantation were studied using organs from 
pigs transgenic for human decay accelerating factor (hDAF, 
hCD55), the porcine kidneys largely maintained plasma elec-
trolyte homeostasis, but an increase in proteinuria and severe 
anemia were detected in the recipient [54]. The anemia, often 
observed in renal pig to non-human primate xenotransplan-
tation, could be related to the inability of porcine erythropoi-
etin to adequately stimulate primate hematopoietic precur-
sors, and treatment of the recipient with exogenous human 
erythropoietin will be required. Alternatively, the generation of 
transgenic pigs producing sufficient amounts of human eryth-
ropoietin may solve the problem.
More difficult is the situation with pig liver transplantation [55]. 
In pig to non-human primate studies, the transplantation of 
livers from pigs transgenic for hCD55 or from GTKO animals, 
which in addition expressed hCD46, was associated with a sur-
vival time of 7 to 9 days [55–57]. Although hepatic functions, 
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Baboon (14) CD55 Cyp, CsA, CS, MMF 99 (26) Bhatti et al., 
1999 [116]
Baboon (10) CD46 ATG, splenectomy, anti-CD20mAb, tacrolimus, 
rapamycin, CS, TPC
113 (76) McGregor et al. 
2004 [117]
Baboon (10) CD55 ATG, anti-CD20mAb, TI, CVF, anti-CD154mAb, MMF, CS 139 (27) Houser et al., 
2004 [118]
Baboon (7) CD46 ATG, splenectomy, anti-CD20mAb, tacrolimus, 
rapamycin, CS, TPC
137 (96) McGregor et al., 
2005 [119]
Baboon (13) CD46 splenectomy, anti-CD20mAb, tacrolimus, rapamycin, 
TPC; heparin + ATG, CyP for rejection episodes
109 (18) Byrne et al., 
2005 [120]
Baboon (8+2) GTKO or low 
expression
ATG, TI, anti-CD2mAb, anti-CD154mAb, CVF, MMF, 
methylprednisolone*
179 (78) Kuwaki et al., 
2005 [44]
Tseng et al., 
2005 [45]
Baboon (63) CD46 Splenectomy, anti-CD20mAb, tacrolimus, rapamycin, 
TPC; aspirin/clopidogref or lovenox or warfarin
139 (96) Byrne et al., 
2006 [46]
Baboon (7) GTKO, CD46, 
TBM or CD55
Anti-CD20mAb, heparin** 130 Iwase et al., 
2015 [43]
Baboon (5) GTKO, CD46, 
TBM
ATG, anti-CD20mAb, CVF, anti-CD40mAb, MMF, CS 945 (298) Mohiuddin et al., 
2013 [392]
Mohiuddin et al., 
2016 [41]
Orthotopic heart transplantation
Baboon (10) CD55 CyP, CsA, CS 9 Schmoeckel et al., 
1998 [21]
Baboon (2) WT Immunosadsorption, TBI, CsA, methotrexate 18, 19 Xu et al., 
1998 [122]
Baboon (1) CD55 CyP, CsA, MMF, CS 39 Vial et al., 
2000 [123]
Baboon (4) CD55 ATG, tacrolimus, rapamycin, CS, GAS914, CyP 25 Brandl et al.,  
2005 [124]
Baboon (4) CD55 CyP, CsA, CS, MMF 20 (14.6) Brenner et al., 
2005 [125]
Baboon (13) CD55/CD46 ATG, CyP, tacrolimus, rapamycin, CS, GAS914 25 Brandl et al., 
2007 [126]
Baboon (14) CD46 or CD55 or 
GTKO/CD55
ATG,or CyP, tacrolimus, rapamycin, anti-CD20mAb 57 (6) Byrne et al., 
2011 [127]
Kidney
Cynomolgus (9) CD55 CyP, CsA, CS, splenectomy 78 (39) Cozzi et al., 
2000 [128]
Cynomolgus (7) CD55 CyP, CsA, MMF, CS 90 (48) Baldan et al., 
2004 [128]
Table 1. Xenotransplantation of organs, longest survival times, up to April 2016.
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including coagulation, have proved to be satisfactory, the im-
mediate development of thrombocytopenia was extremely lim-
iting. The thrombocytopenia resulted in hemorrhages in vari-
ous organs and tissues, as well as in the transplanted liver [56].
Barriers to successful lung transplantation appear to be even 
greater than for other organs [58]. They may be related to an-
atomical factors such as the fragile lung parenchyma-associ-
ated blood supply, as well as the presence of large numbers 
of inflammatory cells. The longest survival of a pig lung after 
transplantation in a non-human primate has been 5 days [58]. 
In contrast to the longer survival times of heart and kidney 
transplantations, lung transplantations are comparable with 
liver transplantation, which reached the longest survival of 9 
days [57].
Microbiological Safety
As already described in the introduction, PERVs are of spe-
cial interest when analyzing the microbiological safety of xe-
notransplantation. Like endogenous retroviruses from other 
species, including humans, they are part of the genome and 
therefore cannot be eliminated, as in many other potentially 
zoonotic microorganisms in pigs, by SPF or DPF breeding [5]. 
PERV-A and PERV-B are in the genome of all pigs; PERV-C is 
common, but not present in all pigs. PERV-A and PERV-B are 
able to infect human cells, but PERV-C infects only pig cells. 
However, recombination between PERV-A and PERV-C result-
ed in recombinant PERV-A/C viruses, which are characterized 
by a very high replication rate. PERV-A/C were not found to 
be integrated in the germ line.
To date, there has been no reported transmission of PERVs in 
more than 200 individuals who had contact with pig tissues, 
either through islet cell transplantation or ex vivo perfusion 
of porcine livers and spleens. PERVs were also not transmit-
ted in preclinical pig to non-human primate transplantations, 
or in infection experiments with small animals or non-human 
primates with or without pharmaceutical immunosuppression 
(for a review, see [5]). However, most of the individuals were 
not exposed for a long time to the xenotransplants and, with 
some exceptions (associated with parallel kidney allotransplan-
tations), no immunosuppression had been applied. Non-human 
primates are not a suitable model in which to study the risk 
of PERV transmission because they (in contrast to humans) 









Baboon (5) GTKO Thymokidney, anti-CD2mAb, WBI, thymectomy, anti-
CD154mAb
83 (26) Yamada et al., 
2005 [49]
Baboon (7) GTKO Thymectomy, splenectomy, TBI, ATG, anti-CD2mAb, 
anti-CD154mAb, tacrolimus, MMF
83 (49) Griesemer et al., 
2009 [130]
Baboon (4) GTKO ATG, anti-CD2mAb, anti-CD154mAb, MMF, CS, 
thymectomy, spelectomy, thymokidney, 
83 (52) Shimizu et al., 
2012 [131]
Baboon (5) CD55 thymokidney, thymectomy, splenectomy, 
immunoadsorption, anti-CD2mAb, anti-CD154mAb, 
ATG, tacrolimus, CyP, CVF, MMF, CS
229 (27) Barth et al., 
2003 [132]
Rhesus (5) GTKO/CD55 Anti-CD4, anti-CD8, anti-CD154mAb, MMF, steroids >133 (6–>133) Higginbotham 





ATG, anti-CD20mAb, CVF, anti-CD40mAb, rapamycin, 
MP##
163 Iwase et al., 
2015 [42]
* Supportive therapy: prostacyclin, dopamine, ganciclovir, levofloxacin, cimetidine, heparin, antithrombin, aspirin; ** two regimens 
were used, first ATG+anti-CD154mAb+CTLA4-Ig, second ATG+anti CD40mAb+CTLA4-Ig; # hTBM and hCD39 were not expressed in 
the kidney; ## in addition anti-inflammatory (tocilizumab, IL-6 receptor blockade, etanervept, TFN-a antagonist) and adjunctive 
(aspirin, low molecular weight heparin) treatment. ATG – anti-thymocyte globulin; CD46 – membrane cofactor protein; CD55 – decay-
accelerating factor; CS – corticosteroids; CsA – cyclosporine; CTLA4-Ig – cytotoxic T-lymphocyte-associated protein 4 coupled to 
immunoglobulin; CVF – cobra venom factor; CyP – cyclophosphamide; EPCR – endothelial protein C receptor, CD39; GAS914 – a soluble 
glycoconjugate comprising Gal on a poly-L-lysine backbone; GTKO – a1,3-galactosyltransferase gene-knockout; MMF – mycophenolate 
mofetil (or analog, e.g. mycophenolate sodium]; MP – methylprednisolone; TBI – total body irradiation; TBM – thrombomodulin; 
TI – thymic irradiation; TPC – an aGal-polyethylene glycol polymer conjugate.
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carry a mutated receptor for PERV, only allowing infection with 
reduced efficacy (reviewed in [59]). Despite the presence of 
a functional receptor for PERV on human cells, no transmis-
sion of PERV was observed in the first clinical trials transplant-
ing pig islet cells to treat diabetes in New Zealand [60] and 
Argentina [61]. Therefore, the question of whether PERVs may 
be transmitted during xenotransplantation is still open and an 
elimination of infectious proviruses is advised.
In contrast to PERVs, transmission of herpesviruses has been 
observed in experimental xenotransplantations, e.g., porcine 
cytomegalovirus (PCMV) from pig to cynomolgus monkeys [62] 
and baboons [63]. Transmission of a baboon cytomegalovirus 
(BCMV) after transplantation of baboon tissues to human re-
cipients was also described [64]. Most of the potentially zoo-
notic microorganisms can be eliminated by Caesarean sec-
tion and SPF or DPF breeding of the animals [65]. However, 
there are viruses that may be transmitted via the placenta and 
therefore may be present even in SPF/DPF facilities [66,67]. At 
present, it is still unclear which porcine microorganisms have 
a zoonotic potential when transmitted to human recipients. 
The following viruses are considered potentially pathogenic: 
PERVs, PCMV, hepatitis E virus (HEV), porcine lymphotropic 
herpesviruses (PLHV-1, -2, and -3), porcine circoviruses (PCV1 
and PCV2), and others (Table 3). PERVs were included on this 
list because retroviruses in general induce tumors and/or im-
munodeficiencies [68]. Examples are human immunodeficiency 
virus 1 (HIV-1), inducing AIDS, and the human T cell lympho-
tropic virus 1 (HTLV-1), inducing lymphoma and neurological 
diseases in humans. HEV is on this list because it has been 
shown to be transmitted from pigs to humans, either by close 
contact or by undercooked pork, causing hepatitis in numer-
ous cases [66,69,70]. PCMV is on the list because it is relat-
ed to human cytomegalovirus (HCMV). HCMV infections are 
in many cases fatal for immunosuppressed allotransplant re-
cipients [71]. Although PCMV is more closely related to HHV-
6 and HHV-7 than to HCMV, designated now as HHV-5 [72], it 
has been shown that transmission of PCMV in pig to non-hu-
man primate kidney transplantation drastically reduced the sur-
vival time of the recipients [62,63], suggesting that PCMV may 
have a similar effect in humans. PLHV-1, -2, and -3 were found 













1 Cynomolgus (2) E None >256
Elliott et al., 
2005 [133]
2 Cynomolgus (4) wt
Anti-CD25mAb, FTY720, 
rapamycin, anti-CD154mAb, 
tacrolimus, rapamycin, CS, TPC
47 to 187
Hering et al., 
2006 [18]




4 to >260 (140)
Cardona et al., 
2006 [17]
4 Cynomolgus (9) wt, GTKO, CD46 ATG; anti-CD154mAb, MMF 5 to 396
Van der Windt 
et al., 2009 [134]
5 Cynomolgus (2) wt
ATG; anti-CD25mAb, anti-
CD20mAb, FTY720, rapamycin, 
CTLA4-Ig
280, 380
Hecht et al., 
2009 [135]
6 Rhesus (9) wt
Anti-CD25mAb, anti-CD40mAb, 
rapamycin, CTLA4-Ig 
47 to 203 (80)
Thompson et al., 
2011 [136]
7 Rhesus (10) GTKO or wt
Anti-CD25mAb, anti-LAF1mAb, 
MMF, CTLA4-Ig 
50 to 249 (137)
Thompson et al., 
2011 [137]
8 Cynomolgus (6) GTKO, CD46,CD39 Anti-CD25mAb 14 to 224
Veriter et al., 
2013 [138]
9 Cynomolgus (5) 3GE – 4GE* Complex treatment** 0 to 365 (106)
Bottino et al., 
2015 [139]
10 Rhesus (5) wt
ATG, CVF, anti-CD154mAb, 
sirolimus
Up to 603
Shin et al., 
2015 [140]
Table 2. Xenotransplantations of islet cells with the longest survival times, up to July 2015.
* 3GE, GTKO,CD46, CD39; 4GE, GTKO,CD46, TFPI, CTL4-Ig; 5GE, GTKO,CD46, TFPI, CTL4-Ig, CD39; ** Prostacyclin, methylprednisolon, 
dextran sulfate, ATG, MMF, anti-CD154mAb. Abbreviations see Table 1.
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lung tissue samples, and in 59%, 26% and 62% of the spleen 
samples, respectively [73]). Approximately 21% (9 of 44) of the 
miniature swine PBMC were also positive for PLHV DNA [74]. 
There is evidence that PLHV-1 is associated with post-transplant 
lymphoproliferative disease (PTLD) in miniature pigs following 
allogeneic hematopoietic stem-cell transplantation [75,76]. The 
clinical symptoms of experimental porcine PTLD, such as fever, 
lethargy, anorexia, high white blood cell count, and palpable 
lymph nodes, are similar to those of human PTLD, which was 
linked to the human herpesvirus Epstein-Barr virus, now des-
ignated HHV-4 [77]. Evidence of productive PLHV-1 infection 
was not detected in recipient baboons receiving different or-
gans from transgenic pigs for up to 6 months of transplant 
function [78]. Appropriate breeding procedures can eliminate 
PLHV and piglets free of PLHV were produced via Caesarean 
section and barrier-reared breeding procedure [74]. In contrast 
to the porcine cytomegalovirus [PCMV], which can be excluded 
from source animals by early weaning of piglets, this was not 
possible in the case of PLHV [79]. With the exception of the 
PERVs, all potentially zoonotic viruses (Table 3) can be eliminat-
ed by SPF/DPF breeding. This includes Caesarean delivery and 
breeding in barrier facilities, and, if necessary, treatment of the 
pig herd with antiviral drugs [66,80]. Most important are the 
quality and sensitivity of the detection method; use of meth-
ods with low sensitivity could result in false-negative results.
Antiviral drugs have still not been used in pigs to treat infec-
tions. Ribavirin may be used for the treatment of HEV infec-
tions and ganciclovir, cidofovir, or other antiviral drugs for the 
treatment of PCMV infections, although PCMV – in contrast 
to the human CMV – is highly resistant to ganciclovir [81]. 
Combining treatment, selection, and (possibly) vaccination of 
the donor pigs, xenotransplantation can become a consider-
ably safer technology compared with allotransplantation, in 
which transmissions of HIV-1, rabies virus, CMV, and other 
pathogens have been described [71].
To prevent transmission of PERVs, which are present in the ge-
nome of all pigs and cannot be eliminated by SPF/DPF breed-
ing [5], several strategies have been developed. First, pigs can 
be selected that have a low copy number and a low expres-
sion at the RNA or protein level of PERV-A and PERV-B provi-
ruses. Methods have been developed to discriminate between 
high and low expression of PERV in blood cells [82,83]. Second, 
PERV-C-free animals can be selected in order to avoid recom-
bination between the ecotropic PERV-C (which infects only pig 
Viruses Zoonotic potential Diseases in pigs
Porcine endogenous retrovirus (PERV) Unknown Unknown (tumour, immunodeficiency?)
Porcine cytomegalovirus (PCMV) Yes Rhinitis*, immunosuppression?
Porcine reproductive and respiratory
syndrome virus (PRRSV)
No PRRS; respiratory diseases in young pigs and 
reproductive diseases in sows
Porcine circovirus type 2 (PCV2) Unknown PCVD; PMWS
Hepatitis E virus (HEV) Yes Subclinical
Menangle virus Yes Reproductive disease
Porcine torovirus (PToV) Unknown Diarrhoea
Porcine sapovirus (porcine SaV) Potential Diarrhoea
Porcine lymphotropic herpesviruses (PLHV) Unknown Unknown but incriminated in PTLD
Nipah virus (NiV) Yes Respiratory and neurological
syndrome
Torque teno sus virus (TTSuV) Unknown Unknown and PMWS
Bungowannah virus  Unknown Porcine myocarditis syndrome
Porcine kobuvirus Unknown Unknown
Porcine bocavirus (PBoV) and other
related novel porcine parvoviruses
Unknown Unknown
Table 3. Potentially zoonotic viruses in pigs.
* Rhinitis in newborn piglets can be severe enough to cause haemorrhage from the nose. PRRS – porcine reproductive and respiratory 
syndrome; PCVD – porcine circovirus 2 diseases, previously; PMWS – post-weaning multisystemic wasting syndrome, PTLD – post-
transplant lymphoproliferative disease.
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cells) and the human-tropic PERV-A. Such recombinant PERV-
A/C are characterized by an increased replication competence 
compared with the parenteral virus [84–87]. Sensitive and 
specific methods have been developed to screen for PERV-C-
positive animals [88,89]. Third, RNA interference technology 
has been successfully used in transgenic pigs to reduce the 
expression of PERV in vitro [90–92] and in vivo [93–95]. Fourth, 
vaccination is an excellent tool to prevent virus transmission. 
Immunizing with the transmembrane and surface envelope 
(TM and SU, respectively) proteins of PERV in different spe-
cies binding and neutralizing antibodies were obtained, sug-
gesting that this may also be possible in humans [96–98]. 
Fifth, since PERV is present in up to approximately 100 copies 
in the genome, it is a challenge to knock out all proviruses in 
the genome using gene editing. When gene editing was per-
formed using the zinc finger nuclease (ZFN), the expression 
of ZFN was very high, inducing a toxic effect when the nucle-
ases were cutting in multiple sites and destabilizing the ge-
nome [99]. When the Clustered Regularly Interspaced Short 
Palindromic Repeats/CRISPR-associated (CRISPR/Cas9) technol-
ogy [100–102] was used, a breakthrough was achieved. Sixty-
two PERV proviruses were knocked-out in immortalized PK-15 
pig cells [103]. If it will be possible to knock out all infectious 
PERV proviruses in primary cells and to obtain piglets not re-
leasing PERV, these retroviruses are no longer a risk for xeno-
transplantation [104]. To summarize, efficient strategies have 
been developed to identify and to prevent transmission of por-
cine microorganisms with zoonotic potential, including PERVs.
Ethical Aspects and Regulation
Although not a topic of this review, it should be mentioned that 
theological-ethical [105–107] and regulatory aspects of xeno-
transplantation are being broadly discussed. The International 
Xenotransplantation Association [IXA] recently published the 
first update of a consensus paper dealing with different aspects 
of efficient and safe islet cell xenotransplantation [108–115]. 
One contribution to this consensus paper provides a detailed 
description of national regulatory frameworks [109].
Conclusions
Here, we demonstrated numerous steps forward to bring xe-
notransplantation towards clinical application. First of all, mul-
titransgenic pigs were created in order to prevent rejection of 
the pig cells and organs. Second, new immunosuppression regi-
mens were introduced, also in order to prevent rejection. Third, 
based on these achievements, longer survival times of trans-
planted pig hearts, kidneys, liver, and islet cells have been ob-
served in preclinical trials. Fourth, new and sensitive methods 
have been developed to screen the donor pigs for potential zoo-
notic microorganisms, making xenotransplantation eventual-
ly safer compared with allotransplantation, where in rare cas-
es HIV-1, rabies virus, HCMV, and other pathogens have been 
transmitted [71]. Fifth, the discussion on ethical aspects is on-
going, an updated consensus document on how to perform safe 
and efficient xenotransplantation was prepared by the scien-
tific community, and in several countries a national regulato-
ry framework was prepared. All these achievements will allow 
clinical application of xenotransplantation in the near future.
Two major fields in xenotransplantation research are in need of 
improvement. First, although pigs with multiple genetic mod-
ifications have been produced with great effort and expense, 
in most cases their advantage compared to other genetically 
modified pigs was not fully evaluated. Second, microbiological 
characterization of the donor pigs has, in the past, not been 
sufficiently thorough, and as a result, pig to non-human pri-
mate transplantations have been performed that resulted in 
the transmission of pathogenic microorganisms and the pre-
mature death of the recipients. For example, the transmission 
of PCMV to cynomolgus monkeys and baboons, significantly 
reducing survival time, has been reported [62,63]. Additional 
financial support and scientific investigations have to be de-
voted to studies of viral safety, the results of which should au-
tomatically contribute to increasing the survival times of xe-
notransplants and their recipients.
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